IP Library Granted Patent US 9,555,069
Granted Patent B2
US 9,555,069 · App. 14/699,676 · Granted Jan 31, 2017

Pharmaceutical compositions comprising plant extracts and methods for reducing duration of a common cold using same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,555,069
App. No.
14/699,676
Granted
Jan 31, 2017
Kind
B2
Abstract

The present disclosure describes pharmaceutical compositions and methods for reducing duration, intensity, and/or bothersomeness of common colds in humans and for reducing severity or duration of common cold symptoms such as nasal congestion, runny nose, watery eyes, dry/scratchy throat and sneezing in humans exhibiting such symptoms. The compositions herein comprise extracts of at least one of Luffa Operculata ( L. operculata ), S. officinale ( V. sabadilla ), and Galphimia Glauca ( G. glauca ) in a pharmaceutically acceptable carrier, and in various embodiments, comprise a mixture of all three Luffa Operculata ( L. operculata ) 10% extract MT, S. officinale ( V. sabadilla ) 3× extract, and Galphimia Glauca ( G. glauca ) 10% extract MT in a pharmaceutically acceptable carrier.

Claims (7)

1. A method for reducing duration of common cold symptoms, said method comprising: nasally administering to a human exhibiting common cold symptoms a therapeutically effective amount of a composition comprising: (a) from about 0.001 wt. % to about 0.5 wt. % of a mixture of L. operculata 10 wt. % extract (MT), S. officinale 3× extract, and G. glauca 10 wt. % extract (MT); (b) from about 0.001 wt. % to about 10 wt. % of a thickener; (c) from about 0.001 wt. % to about 10 wt. % of a surfactant; (d) from about 0.01 wt. % to about 10 wt. % of an organic acid; (e) from about 0.01 wt. % to about 10 wt. % of an alkaline material; (f) from about 0.001 wt. % to about 1 wt. % of an inhalant; (g) from about 0.01 wt. % to about 10 wt. % of an α-amino acid; and (h) from about 90 wt. % to about 99 wt. % water, wherein each wt. % is based on the total weight of the composition, wherein the common cold sypmtoms are selected from the group consisting of: nasal congestion, runny nose, watery eyes, dry/scratchy throat and/or sneezing.

2. The method according to claim 1 , wherein said inhalant is selected from the group consisting of anethole, menthol, eucalyptol, borneol, borneol acetate, camphor, 1,8-cineole, cinnamaldehyde, benzaldeyhde, citral, thujone, eugenol, limonene, geraniol, citronellol, citronellal, pinene, linalool, thymol, carvone, caryphyllene, linalyl acetate, methyl salicylate, and mixtures thereof.

3. The method according to claim 1 , wherein said inhalant is selected from the group consisting of eucalyptol, eugenol, menthol, camphor, and mixtures thereof.

4. The method according to claim 1 , wherein said α-amino acid is selected from the group consisting alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, L-lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and mixtures thereof.

5. The method according to claim 1 , wherein said α-amino acid is selected from the group consisting of glycine, L-lysine, and mixtures thereof.

6. The method according to claim 1 , wherein said composition further comprises 2-phenylethanol at a level of about 0.001 wt. % to about 1 wt. %, based on the total weight of the composition.

7. A method for reducing duration of common cold symptoms, said method comprising: nasally administering to a human exhibiting common cold symptoms a therapeutically effective amount of a composition comprising: (a) from about 0.001 wt. % to about 0.5 wt. % of a mixture of L. operculata 10 wt. % extract (MT), S. officinale 3× extract and G. glauca 10 wt. % extract (MT); (b) from about 0.5 wt. % to about 1.5 wt. % of a cellulosic thickener; (c) from about 0.01 wt. % to about 1 wt. % of a surfactant; (d) from about 0.1 wt. % to about 1 wt. % of an organic acid; (e) from about 0.1 to about 2 wt. % of at least one alkaline material; (f) from about 0.001 wt. % to about 1 wt. % of an inhalant selected from the group consisting of eucalyptol, eugenol, menthol, camphor, and mixtures thereof; (g) from about 0.05 wt. % to about 0.5 wt. % of an amino acid; (h) from about 0.1 wt. % to about 1 wt. % sodium chloride; and (i) from about 90 wt. % to about 99 wt. % water, wherein each wt. % is based on the total weight of the composition, wherein the common cold symptoms are selected from the group consisting of: nasal congestion, runny nose, watery eyes, dry/scratchy throat and/or sneezing.

Assignments (6)
MERGER Recorded Jan 27, 2021
From: MATRIXX INITIATIVES, INC.
To: CHURCH & DWIGHT CO., INC.
Reel/Frame 055050/0807 →
RELEASE OF SECURITY AGREEMENT AT REEL/FRAME 044405/0304 Recorded Dec 2, 2020
From: MIDCAP FINANCIAL TRUST
To: MATRIXX INITIATIVES, INC.
Reel/Frame 054570/0935 →
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 2, 2020
From: CORTLAND CAPITAL MARKET SERVICES LLC
To: MATRIXX INITIATIVES, INC.
Reel/Frame 054572/0156 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 19, 2017
From: MATRIXX INITIATIVES, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 044908/0001 →
SECURITY INTEREST Recorded Dec 15, 2017
From: MATRIXX INITIATIVES, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 044405/0304 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2015
From: CLAROT, TIM; ASCARATE, ARLENE M.
To: MATRIXX INITIATIVES, INC.
Reel/Frame 035558/0713 →